[{"id":"af57e4ca-b38a-471a-ada9-a8cecac2e850","acronym":"","url":"https://clinicaltrials.gov/study/NCT01433172","created_at":"2021-01-18T05:55:23.773Z","updated_at":"2024-07-02T16:36:57.332Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer","source_id_and_acronym":"NCT01433172","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CCL21","pipe":"","alterations":" ","tags":["CCL21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GM.CD40L cell vaccine"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 03/26/2012","start_date":" 03/26/2012","primary_txt":" Primary completion: 01/31/2016","primary_completion_date":" 01/31/2016","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2019-08-06"},{"id":"08338ec0-6078-48e0-bc33-7c4d40eba740","acronym":"MEL58","url":"https://clinicaltrials.gov/study/NCT01585350","created_at":"2021-01-18T06:45:23.070Z","updated_at":"2024-07-02T16:37:29.831Z","phase":"Phase 1","brief_title":"A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients","source_id_and_acronym":"NCT01585350 - MEL58","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5","pipe":"","alterations":" ","tags":["MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-08-12"}]